Zogenix rockets up as PhIII study offers impressive data on Dravet syndrome, vaulting over a rival
Zogenix offered investors exactly the kind of gourmet data they were looking for this morning with a clean sweep of promising data for its late-stage drug ZX008, designed to tackle a severe form of childhood epilepsy. And the news powered a big spike in its share price $ZGNX as Wall Street continues to shower rewards on clear successes.
The first of two Phase III studies for this drug, researchers say they tracked a clear dose-dependent response for this treatment, with a dramatic drop in the rate of seizures experienced by patients with Dravet syndrome.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.